UPDATE: Stifel Downgrades Inovio Pharmaceuticals (INO) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. CAT
7. AA
8. RKLB
9. RXRX
10. NOW

Go back to UPDATE: Stifel Downgrades Inovio Pharmaceuticals (INO) to Hold

Inovio Pharma (INO) Reports Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

June 30, 2020 7:31 AM EDT

(Updated - June 30, 2020 7:37 AM EDT)

INOVIO (NASDAQ: INO) today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition, INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Furthermore, INOVIO has expanded its Phase 1 trial to add older participants in additional cohorts and plans to initiate a Phase 2/3... More